Compare Jones Lang LaSalle Inc (JLL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Pfizer Inc — how do they compare? Jones Lang LaSalle Inc trades at $299.41 (market cap $13.95B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 11.4× Jones Lang LaSalle Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Pfizer Inc for 158 Days on average.
| JLL | PFE | |
|---|---|---|
Market Cap | $13.95B | $158.56B |
Volume | 457,462 | 44,138,282 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $29.02 |
52-Week Low | $280.16 | $23.67 |
Typical Hold Time | 71 Days | 158 Days |
Enterprise Value | $16.71B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% over 24 hours, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 14.54, P/S of 0.53, and net income margin of 3.64%. Recent earnings have consistently beaten expectations, and cash flow from operations reached $1.19 billion in 2025. Analyst consensus is bullish with a $450.50 price target, supported by positive news on acquisitions and growth prospects.
The outlook for JLL is positive due to robust earnings growth, improving profit margins, and strategic acquisitions. Risks include market volatility, competitive pressures in real estate services, and economic sensitivity. Institutional sentiment remains strong, with a majority of analysts recommending buy. The stock presents a value opportunity if it can sustain its operational momentum amid broader market headwinds.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
